BioSpace News Archive

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine candidate in rabbits.

Orion Biotechnology Canada Ltd, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors, announced that it will be presenting important new data at the GPCRs-Targeted Drug Discovery Summit, taking place this week - March 22-24, 2022.

OBiO Technology Corp., Ltd., has completed its initial public offering process and started trading on the Shanghai Stock Exchange’s Sci-Tech innovation board.

Telemedicine and virtual office visits experienced exponential growth during the COVID-19 pandemic to help facilitate the safe delivery of orthopaedic care for numerous patient populations, including pediatric.

Valbiotis is strengthening its commitment to Corporate Social Responsibility by joining the United Nations Global Compact and applying the ISO 26000 standard.

Nanomerics Ltd., a private speciality pharmaceutical company, announced the receipt of a further milestone payment on agreeing the expansion of its anti-viral spray licence to Virpax Pharmaceuticals.

LumiThera Inc. announced positive findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular Age-Related Macular Degeneration subjects treated with the Valeda® Light Delivery System.

Depressive disorder is associated with longer in-hospital length of stay, higher rates of medical complications, and increased healthcare costs for patients undergoing reverse shoulder arthroplasty for the treatment of glenohumeral osteoarthritis, according to a large-scale study presented at the 2022 Annual Meeting of the American Academy of Orthopaedic Surgeons.

When patients over 80 years old are a candidate for total knee arthroplasty, there are concerns regarding medical and implant-related complications from the procedure due to their age.

Calliditas Therapeutics AB announced that the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency can be expected in Q2, 2022.